摘要
目的:观察抗CD_3单克隆抗体激活的杀伤细胞(CD_3AK细胞)对恶性肿瘤患者细胞免疫功能的影响。方法:65例恶性肿瘤病人分为两组,实验组(CD_3AK细胞+化疗)35例,对照组(单纯化疗)30例,两组病人分别于治疗前及治疗后作外周血T细胞亚群和血清可溶性白细胞介素2受体(sIL-2R)水平测定。结果:恶性肿瘤病人细胞免疫功能均较正常人低,化疗病人辅以CD_3AK细胞治疗后外周血CD_3^+、CD_4^+ T细胞及CD_4^+/CD_8^+比值均明显升高,sIL-2R水平显著下降;对照组病人经化疗后CD_3^+、CD_4^+ T细胞与CD_4^+/CD_8^+比值明显下降,sIL-2R水平也下降,但其下降幅度比CD_3AK细胞治疗组小,两者比较有统计学意义(P<0.05)。结论:CD_3AK细胞能有效地提高化疗中恶性肿瘤患者的细胞免疫功能。
Objective:To observe the effect of anti-CD3 monoclonal antibody activated killer cells (CD3AK)on cellular immune function of patients with malignant tumor. Methods: Clinical trial was performed 65 patients were divided into the treatment group (CD3AK + chemotherapy, 35 patients) and the control group (chemotherapy alone, 30 patients), theT cell subsets in the peripheral blood and the level of sIL-2R were examined both before and after the treatment. Result:The cellular immune function of patients with malignant tumor was lower than that of the healthy controls. After CD3AK cells treatment and chemotherapy, the CD3+, CD4+ T cell subsets and CD4+ /CD8+ ratio in the peripheral blood of patients with malignant tumor increased significantly, and the level of sIL-2R decreased significantly. In malignant tumor patients who were only treated by chemotherapy, the CD3+, CD4+ T cell subsets and CD4+ /CD8+ ratio decreased markedly, the level of sIL-2R decreased also, but it was higher than that of the group of CD3AK cells treatment and chemotherapy (P< 0.05). Conclusion; CD3AK cells can enhance the cellular immune function of patients with malignant tumor effectively.
出处
《中国医学文摘（肿瘤学）》
2002年第2期193-194,共2页
Journal of Chinese Medical Abstracts·Oncology
基金
广西自然科学基金(桂攻科9316083)
